Hexarelin vs GHRP-6

Hexarelin was built from the GHRP-6 template and is more potent at releasing GH; it also binds CD36 in heart tissue, which is why it appears in cardiac research. GHRP-6 remains the reference compound for ghrelin-like appetite effects.

HPLC tested · JanoshikJanoshik CertificatesNationwide DeliveryResearch Only

🧪

Hexarelin

A potent synthetic growth-hormone-releasing hexapeptide with additional, receptor-mediated actions studied in cardiovascular models.

BEST STUDIED FOR

GH secretagogues

Read the cited profile →

🧪

GHRP-6

One of the first synthetic growth-hormone-releasing hexapeptides, a ghrelin-receptor agonist studied for GH release and as a diagnostic probe.

BEST STUDIED FOR

GH secretagogues

Read the cited profile →

SIDE BY SIDE

	Hexarelin	GHRP-6
The key difference	Highest potency; cardiac CD36 effects	Pronounced appetite stimulation
Class	GH secretagogues	GH secretagogues
Mechanism	Hexarelin activates the ghrelin receptor (GHSR) and releases GH.	GHRP-6 binds the ghrelin receptor (GHS-R1a) and stimulates pituitary GH release; it was used to characterise that receptor before ghrelin itself was discovered.
Status	Preclinical and small human studies; not an approved medicine.	A research and diagnostic tool from the 1990s onward; not an approved medicine. Banned in sport.
Reported safety signals	Like other GHRPs it can raise cortisol and prolactin; attenuation of the GH response with repeated exposure has been reported. No long-term human safety data.	Older diagnostic studies used single doses. Class-wide, GHRPs raise cortisol/prolactin and increase hunger; there are no long-term human safety data.
A key study	Reviews evidence that hexarelin, via peripheral GHSR in heart and vessels, may have direct cardiovascular effects. (J Geriatr Cardiol 2014, PMID 25278975)	Assessed GHRP-6 as a provocative test of pituitary GH reserve in the diagnosis of GH deficiency. (J Pediatr Endocrinol Metab 1996, PMID 8887178)

WHEN TO RESEARCH WHICH

Hexarelin for cardiac and high-potency GH questions; GHRP-6 for appetite-linked ghrelin-receptor work. Both are discussed here strictly as research compounds; nothing on this page is medical advice or a dosing guide.

REFERENCES (PUBMED)

[Hexarelin] The cardiovascular action of hexarelin — J Geriatr Cardiol 2014. PMID 25278975
[Hexarelin] The Safety and Efficacy of Growth Hormone Secretagogues — Sex Med Rev 2018. PMID 28400207
[Hexarelin] Hexarelin alleviates apoptosis on ischemic acute kidney injury via MDM2/p53 pathway — Eur J Med Res 2023. PMID 37710348
[GHRP-6] Growth hormone releasing hexapeptide-6 (GHRP-6) test in the diagnosis of GH-deficiency — J Pediatr Endocrinol Metab 1996. PMID 8887178
[GHRP-6] Growth hormone-releasing peptides and their analogs — Front Neuroendocrinol 1998. PMID 9465289
[GHRP-6] Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males — Transl Androl Urol 2020. PMID 32257855

FREQUENTLY ASKED

What is the difference between Hexarelin and GHRP-6?

What is the regulatory status of Hexarelin and GHRP-6?

Hexarelin: Preclinical and small human studies; not an approved medicine. GHRP-6: A research and diagnostic tool from the 1990s onward; not an approved medicine. Banned in sport.

What safety signals have been reported?

Hexarelin: Like other GHRPs it can raise cortisol and prolactin; attenuation of the GH response with repeated exposure has been reported. No long-term human safety data. GHRP-6: Older diagnostic studies used single doses. Class-wide, GHRPs raise cortisol/prolactin and increase hunger; there are no long-term human safety data.

Which studies is this comparison based on?

For Hexarelin: “The cardiovascular action of hexarelin” (PMID 25278975); “The Safety and Efficacy of Growth Hormone Secretagogues” (PMID 28400207); “Hexarelin alleviates apoptosis on ischemic acute kidney injury via MDM2/p53 pathway” (PMID 37710348). For GHRP-6: “Growth hormone releasing hexapeptide-6 (GHRP-6) test in the diagnosis of GH-deficiency” (PMID 8887178); “Growth hormone-releasing peptides and their analogs” (PMID 9465289); “Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males” (PMID 32257855).